---
title: 'High-precision stereotactic irradiation for focal drug-resistant epilepsy
  versus standard treatment: a randomized waitlist-controlled trial (the PRECISION
  trial)'
date: '2024-05-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38773643/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240522182830&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: The standard treatment for patients with focal drug-resistant
  epilepsy (DRE) who are not eligible for open brain surgery is the continuation of
  anti-seizure medication (ASM) and neuromodulation. This treatment does not cure
  epilepsy but only decreases severity. The PRECISION trial offers a non-invasive,
  possibly curative intervention for these patients, which consist of a single stereotactic
  radiotherapy (SRT) treatment. Previous studies have shown promising results of SRT
  in ...'
disable_comments: true
---
INTRODUCTION: The standard treatment for patients with focal drug-resistant epilepsy (DRE) who are not eligible for open brain surgery is the continuation of anti-seizure medication (ASM) and neuromodulation. This treatment does not cure epilepsy but only decreases severity. The PRECISION trial offers a non-invasive, possibly curative intervention for these patients, which consist of a single stereotactic radiotherapy (SRT) treatment. Previous studies have shown promising results of SRT in ...